MarketCapExport financials
Forte Biosciences (FBRX)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Forte Biosciences Financial Ratios 2025-2011 | FBRX
Brief overview of Forte Biosciences's valuation multiples
The review covers five available annual periods spanning 2021 to 2025.
Market valuation is represented by EV/EBITDA 1.11x (median 1.11x), P/B 5.5x (median 0.69x). On average, this basket is 348.3% above its own five-year medians. The market is pricing in elevated future expectations.
Returns on assets and capital are represented by ROE -113.7%, ROA -83.8%, ROCE -115.8%. Current return ratios are negative, materially weakening the fundamental profile.
Valuation takeaway
Forte Biosciences's multiples are demanding relative to current business quality. Material improvement is needed to justify them.
Annual Financial Ratios Forte Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-4.8 | -1.5 | -0.0 | -1.2 | -1.4 | -8.2 | -37.9 | -66.8 | -71.7 | - | - | - | - | - | - |
P/S |
- | - | - | - | - | - | - | 181.4 | 68089.2 | - | - | - | - | - | - |
EPS |
-4.7 | -12.2 | -24.9 | -0.8 | -1.6 | -6.3 | -1.9 | -2.4 | -2.7 | -15.2 | -10.6 | - | - | - | - |
EV (Enterprise Value) |
280 M | 39.3 M | -36.2 M | -24.1 M | -12.2 M | 323 M | 158 M | 3.27 B | 2.78 B | 22.8 M | 14.9 M | - | - | - | - |
EBITDA per Share |
-5.45 | -5.72 | -22.4 | -0.8 | -1.54 | -1.26 | -3.03 | -33.8 | -38.3 | - | - | - | - | - | - |
EV/EBITDA |
-4.0 | -1.1 | 1.1 | 1.7 | 0.7 | -22.6 | -36.4 | -72.0 | -73.9 | - | - | - | - | - | - |
PEG |
-0.01 | -0.0 | -0.0 | 0.03 | - | 0.01 | -0.41 | -7.93 | 1.52 | - | - | - | - | - | - |
P/B |
5.5 | 1.0 | 0.0 | 0.4 | 0.7 | 6.4 | -32.4 | 56.3 | 39.3 | - | - | - | - | - | - |
P/CF |
-6.6 | -1.7 | -0.0 | -2.1 | -1.8 | -20.6 | -52.6 | -89.8 | -87.8 | - | - | - | - | - | - |
ROE % |
-113.75 | -67.60 | -89.13 | -35.75 | -52.25 | -78.82 | 85.30 | -84.19 | -54.77 | - | - | - | - | - | - |
ROA % |
-83.81 | -57.63 | -80.75 | -33.05 | -50.13 | -75.91 | -53.14 | -47.49 | -42.28 | - | - | - | - | - | - |
ROCE % |
-115.85 | -69.74 | -91.99 | -35.80 | -51.71 | -24.12 | -70.75 | -52.98 | -50.34 | - | - | - | - | - | - |
Current Ratio |
3.8 | 6.8 | - | - | - | 26.5 | 3.9 | 5.9 | 5.2 | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Financial Ratios Forte Biosciences
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-0.96 | -1.24 | - | -0.99 | -0.96 | -1.37 | - | -4.54 | -0.27 | -0.16 | - | -0.26 | -0.42 | -0.32 | - | -0.18 | -0.21 | -0.17 | - | -0.54 | -0.43 | -0.36 | - | -0.45 | -9.52 | -0.97 | -0.45 | -330 | -300 | -0.74 | -0.96 | -0.02 | -0.81 | -0.65 | -0.55 | -0.5 | -0.56 | -4.11 | -3.83 | -4.09 | -3.66 | -3.64 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
-0.89 | -1.61 | - | - | - | -2.45 | - | - | - | -0.21 | - | - | - | - | - | -0.18 | -0.2 | -0.17 | - | -0.54 | -0.42 | -0.36 | - | -0.44 | -9.51 | - | - | - | - | -0.72 | - | 0.09 | -0.76 | -0.64 | - | -0.48 | -0.52 | -3.84 | - | -3.79 | -3.41 | -3.41 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
-114.84 | -125.75 | -73.18 | -162.78 | -215.51 | -229.97 | -189.23 | -213.87 | -160.02 | -106.75 | -80.88 | -88.82 | -72.13 | -42.79 | -22.29 | -40.05 | -43.76 | -44.59 | -38.19 | -46.83 | -88.01 | -79.84 | -71.06 | 150.85 | 173.97 | 246.12 | 238.67 | 2680.21 | 2665.08 | 2624.20 | 2612.97 | -65.73 | -79.07 | -64.15 | -54.77 | -32.74 | -11.51 | 7.71 | 26.91 | 7.23 | 6.46 | 6.43 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
-80.49 | -94.57 | -61.64 | -108.40 | -138.16 | -150.90 | -117.91 | -138.70 | -120.47 | -90.89 | -67.72 | -75.25 | -62.10 | -39.79 | -21.39 | -37.75 | -41.20 | -41.98 | -35.76 | -44.09 | -84.50 | -76.86 | -68.44 | -206.63 | -207.32 | -158.78 | -159.64 | -40.46 | -31.82 | -39.20 | -47.49 | -40.24 | -50.68 | -44.92 | -42.28 | -54.36 | -69.01 | -81.91 | -94.70 | -25.46 | -22.75 | -22.65 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
-108.96 | -128.86 | -75.56 | -167.69 | -221.41 | -236.87 | -194.91 | -220.19 | -164.37 | -109.60 | -82.39 | -90.38 | -73.01 | -42.98 | -22.17 | -39.81 | -43.33 | -44.10 | -37.82 | -46.31 | -87.60 | -79.52 | -70.85 | -56.51 | -34.83 | -131.43 | -127.99 | -125.54 | -166.24 | -201.52 | -46.00 | -59.70 | -74.32 | -60.00 | -37.90 | -31.05 | -11.22 | 7.03 | 19.06 | 6.86 | 6.12 | 6.08 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
3.8 | 2.7 | 6.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.7 | 0.4 | 0.1 | 0.2 | 0.6 | 2.3 | 2.3 | 2.3 | 2.3 | 4.4 | 4.4 | 4.4 | 4.4 | 1.2 | 1.2 | 1.2 | 1.2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Multiples are an important financial analysis tool for the company Forte Biosciences, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Britain
USA
Schweiz
Canada
Danmark
